Fig. S1.

Nuclear NICD1 is elevated in advanced human prostate cancer. The figure shows negative and positive controls for the human prostate TMA stained with an antibody against the intracellular domain of Notch1 presented in Fig. 1A. (Left) Benign human tissue; epithelial cells are negative for NICD1. (Center) Previously described mouse Myc-CAP xenografts (41). Myc-CAP xenografts are negative for nuclear NICD1. (Right) As a positive control we used tumors driven by the combination of NICD1 overexpression and active AKT overexpression (myrAKT). (Scale bars: 100 microns in the upper row; 50 microns in the lower row.)